Biocept has announced the commercial availability of its liquid biopsy test for progesterone receptor (PR), which can be used for the detection and monitoring of a key biomarker in the blood of patients with breast cancer. The company noted that the ability to detect PR expression in circulating tumor cells complements its existing ER and HER2 assays for biomarker analysis in breast cancer. Biocept's Target Selector PR expression test is performed on circulating tumor cells using fluorescently labeled antibodies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Cancer researcher Alan Rabson has died at 92, the New York Times reports.

As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.

In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.

The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.